This section of the website is for UK healthcare professionals only. If you are not a healthcare professional, please click here.
This section of the website is for UK healthcare professionals only. If you are not a healthcare professional, please click here.

Training and Resources

LYNPARZA™ (olaparib) in Prostate Cancer

 

More information about LYNPARZA™ (olaparib) in Prostate Cancer:

LYNPARZA is indicated as monotherapy for the treatment of adult patients with metastatic castration-resistant prostate cancer and BRCA1/2-mutations (germline and/or somatic) who have progressed following prior therapy that included a new hormonal agent.1

Reference

  1. LYNPARZA (tablets) Summary of Product Characteristics.

Supporting documentation

100 mg and 150 mg film coated tablets – Great Britain
Prescribing Information | Summary of Product Characteristics | Patient Information Leaflet

100 mg and 150 mg film coated tablets – Northern Ireland
Prescribing Information | Summary of Product Characteristics | Patient Information Leaflet

GB-27141 | Date of Preparation: March 2021